Why is Novo Nordisk stock sliding today?

Novo Nordisk's stock experienced a 2.4% decline, trading at 297.8 Danish kroner following a downgrade from Deutsche Bank. Analyst Emmanuel Papadakis, citing mixed results and upcoming capital markets day uncertainties, reduced the price target from 290 to 265 kroner, moving the stock to a Sell rating from Hold. This marks one of the most bearish assessments from a major investment bank in recent times, bringing the sell-side rating distribution to five buys, eighteen holds, and two sells.

The downgrade arrives amidst a challenging period since the Q2 2026 earnings release on August 4, where the stock fell despite management raising its full-year outlook, as investors focused on Wegovy's prescription trajectory falling below expectations and pipeline setbacks like the failed Ziltivekimab cardiovascular trial. A prior Berenberg downgrade to Hold on August 12 added to the pressure.

Despite recovering from its 52-week low of 224.3 kroner, shares have remained below their 52-week high of 410 kroner. Competitively, Eli Lilly's widening lead in the GLP-1 obesity drug space, with its oral weight-loss treatment receiving European approval, further challenges Novo Nordisk's Wegovy franchise. The broader U.S. markets remained modestly positive, but the company-specific weaknesses highlighted by Deutsche Bank's sell rating and reduced price target have crystallized investor concerns over Novo Nordisk's near-term growth, pipeline, and competitive standing, leading to today's decline.